Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
NCT03840421Phase 3Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Apr 2019
- Primary completion
- Aug 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoint: Progression-Free Survival at 3 years. Started Apr 2019; status: active, not recruiting.
02
Drugs
gemcitabine
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03840421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03840421.